News
After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry ‘This kid died from the same thing we’re trying to fight off right now,’ one parent says ...
In its complete response letter, the FDA cited insufficient evidence establish deramiocel's effectiveness for cardiomyopathy ...
Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene therapy, Elevidys, designed for Duchenne muscular dystrophy (DMD ...
Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...
The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...
Duchenne muscular dystrophy affects approximately 15,000 people in the United States, primarily boys. The genetic disorder disrupts production of dystrophin, a protein essential for muscle function.
Sarepta is facing a shareholder lawsuit over ELEVIDYS-related deaths. Robbins LLP cites safety risks and stock losses.
The company said it was optimistic that the issues identified by the Food and Drug Administration could be resolved with new data.
Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...
TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.
Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results